Survodutide
Survodutide is a synthetic peptide designed to activate both glucagon and GLP-1 receptors, which are involved in regulating metabolism, appetite, and energy balance. By targeting these pathways together, it has been studied for its effects on weight reduction and metabolic health. The compound remains investigational and is being evaluated in clinical research.
About the product
Survodutide is a modified peptide based on glucagon and GLP-1 analog structures. It includes amino acid substitutions and lipidation (attachment of a fatty acid chain) to improve stability and extend its half-life. These modifications allow for sustained receptor activation.
Survodutide activates both GLP-1 and glucagon receptors. GLP-1 receptor activation reduces appetite and slows gastric emptying, while glucagon receptor activation increases energy expenditure. The combined effect targets multiple aspects of metabolic regulation.
Survodutide is studied for its role in weight management and metabolic regulation. Clinical studies report reductions in body weight and improvements in metabolic markers. Research is also exploring its effects on liver health and related metabolic conditions.
Reported side effects include nausea, vomiting, and gastrointestinal discomfort, which are common with GLP-1–based therapies. These effects are usually mild to moderate and tend to decrease over time. Long-term safety continues to be evaluated in ongoing clinical trials.
Survodutide is synthesized using solid-phase peptide synthesis with additional chemical modifications to introduce lipidation. After synthesis, the peptide is purified using high-performance liquid chromatography and verified by mass spectrometry to ensure identity and purity.
Survodutide is an investigational peptide and has not received approval from major regulatory authorities for general therapeutic use. It remains in clinical development.
Clinical dosing is being established in ongoing studies and varies depending on the treatment protocol. Standardized dosing guidelines are not yet defined.
- Do follow approved clinical or research protocols.
- Do monitor metabolic and gastrointestinal responses during studies.
- Don’t combine with other metabolic agents without study justification.
- Don’t use outside controlled research settings.
- Q: What type of peptide is survodutide?
- A: It is a dual agonist targeting GLP-1 and glucagon receptors.
- Q: What is it studied for?
- A: It is studied for weight management and metabolic health.
- Q: How is it different from GLP-1 peptides?
- A: It also activates glucagon receptors, which may increase energy expenditure.
To guarantee authenticity and quality, we only sell through approved partners. Check our list of Verified Vendors to make sure you're buying the real thing.
Compound Overview
Related Peptides
